Cross Shore Discovery Fund | | | | | | | | | | | | | |
Schedule of Investments (Unaudited) | | | | | | | | | | | | | |
December 31, 2023 | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | Next | |
| | | | | | | | Initial | | | | Available | |
| | % of | | | | | | Acquisition | | Redemption | | Redemption | |
Portfolio Funds* | | Net Assets | | Cost(1) | | Fair Value | | Date | | Frequency(2) | | Date | |
| | | | | | | | | | | | | |
Long/Short Generalist: | | | | | | | | | | | | | |
Atika Offshore Fund, Ltd., Class A, Series 1 | | 4.5% | | $ 677,447 | | $ 1,445,365 | | 1/2/2015 | | Quarterly | | 3/31/2024 | |
| | | | | | | | | | | | | |
EVR Offshore Partners Fund, Ltd., Class B, Series 1121 | | 4.5% | | 1,312,500 | | 1,444,943 | | 11/1/2021 | | Quarterly | | 3/31/2024 | (3) |
| | | | | | | | | | | | | |
Hawk Ridge Partners Offshore, Ltd., Class A, Initial Series | | 9.0% | | 1,600,000 | | 2,904,335 | | 2/1/2018 | | Quarterly | | 3/31/2024 | |
| | | | | | | | | | | | | |
Hill City Capital Offshore Fund Ltd., Class A, Series 14 | | 4.8% | | 1,312,500 | | 1,555,529 | | 11/1/2021 | | Quarterly | | 3/31/2024 | (3) |
| | | | | | | | | | | | | |
TCIM Offshore Fund Ltd., Class A-33, Series 2019-12 | | 8.2% | | 1,756,890 | | 2,635,809 | | 12/1/2019 | | Monthly | | 1/31/2024 | |
| | | | | | | | | | | | | |
Wolf Hill Offshore Fund, Ltd., Class A-OS, Series 2020-08 | | 5.0% | | 1,300,000 | | 1,601,980 | | 7/1/2021 | | Quarterly | | 3/31/2024 | |
| | | | | | | | | | | | | |
Total Long/Short Generalist | | 36.0% | | 7,959,337 | | 11,587,961 | | | | | | | |
| | | | | | | | | | | | | |
Long/Short Sector: | | | | | | | | | | | | | |
Energy | | | | | | | | | | | | | |
Encompass Capital Fund Offshore Ltd., Class A, Series 1 | | 10.6% | | 1,803,039 | | 3,399,717 | | 1/1/2020 | | Quarterly | | 3/31/2024 | |
| | | | | | | | | | | | | |
Healthcare, Biotechnology | | | | | | | | | | | | | |
Avoro Life Sciences Offshore Fund Ltd., Class A-1 | | 13.4% | | 1,069,545 | | 4,325,706 | | 5/1/2017 | | Quarterly | | 3/31/2024 | |
Biomedical Offshore Value Fund, Ltd., Class I, Series 200199-1 | | 10.7% | | 2,100,000 | | 3,448,585 | | 1/1/2019 | | Quarterly | | 3/31/2024 | |
| | | | | | | | | | | | | |
Total Healthcare, Biotechnology | | 24.1% | | 3,169,545 | | 7,774,291 | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Technology, Media and Telecommunications | | | | | | | | | | | | | |
Atreides Foundation Fund, Ltd., Founders Class, Series F-2 | | 5.9% | | 1,189,143 | | 1,878,089 | | 5/15/2019 | | Quarterly | | 3/31/2024 | (3) |
| | | | | | | | | | | | | |
Total Long/Short Sector | | 40.6% | | 6,161,727 | | 13,052,097 | | | | | | | |
| | | | | | | | | | | | | |
Total Investments In Portfolio Funds | | 76.6% | | $ 14,121,064 | | $ 24,640,058 | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | % of | | | | | | | | | | | |
Money Market Funds | | Net Assets | | Cost | | Fair Value | | Shares | | | | | |
| | | | | | | | | | | | | |
Federated Hermes Institutional Prime Obligations Fund, | | | | | | | | | | | | | |
Institutional Class, 5.45%(4) | | 11.6% | | $ 3,747,300 | | $ 3,749,602 | | 3,746,604 | | | | | |
| | | | | | | | | | | | | |
Total Investments | | 88.2% | | $ 17,868,364 | | $ 28,389,660 | | | | | | | |
| | | | | | | | | | | | | |
Other Assets in Excess of Liabilities | | 11.8% | | | | $ 3,800,447 | | | | | | | |
| | | | | | | | | | | | | |
Net Assets | | 100.0% | | | | $ 32,190,107 | | | | | | | |
| | | | | | | | | | | | | |
* Non-income producing security. | | | | | | | | | | | | | |
(1) There were no unfunded capital commitments as of December 31, 2023. | | | | | | | | | | |
(2) Certain redemptions may be subject to various restrictions and limitations such as redemption penalties on investments liquidated within a certain period subsequent to investment (e.g., a soft or hard lock-up), investor-level gates and/or Portfolio Fund-level gates. Redemption notice periods range from 30 to 120 days. | |
(3) Subject to 25% investor level quarterly gate. | | | | | | | | | | |
(4) Rate disclosed is the seven day effective yield as of December 31, 2023. | | | | | | | | | | |
| | | | | | | | | | | | | |